series-c-plus
Stage
1
Investors
About
Skye Bioscience, Inc is a biotechnology company developing next-generation drugs that target G-protein coupled receptors, primarily focusing on a peripheral CB1 receptor inhibitor called nimacimab to treat obesity and related metabolic diseases.
Explore Skye Bioscience, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.